Publications

The following are select publications from our team and collaborators:
  1. Davicioni E, Anderson JA, Buckley JD, Meyer WM, and Triche TJ. Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas- a report from the Children’s Oncology Group. J Clin Oncol 2010; manuscript in press.

  2. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009 15(5) 402-15.

  3. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Path. 2009 174(2):550-564.

  4. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-85.

  5. Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009;27:3929-37.

  6. Black PC and Dinney CP Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008 9(1): 55-61.

  7. Agarwal PK, Black PC, Kamat AM Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008; 26(1):39-44.

  8. Davicioni E, Wai DH, Anderson MJ. Diagnostic and Prognostic Sarcoma Signatures. Mol Diagn. Ther. 2008 12(6):359-74.

  9. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB.A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008;3(5):e2318. Epub 2008 May 28.

  10. Abdueva D, Wing MR, Schaub B, Triche TJ. Experimental comparison and evaluation of the Affymetrix exon and U133Plus2 GeneChip arrays. PLoS ONE. 2007 Sep 19;2(9):3913

  11. Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007;7:1717-27.

  12. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas. Cancer Res. 2006 Jul 15;66(14):6936-46.

  13. Asgharzadeh S. Pique-Regi R. Sposto R. Wang H. Yang Y. Shimada H. Matthay K. Buckley J. Ortega A. Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Journal of the National Cancer Institute. 2006 Sep 6; 98(17):1193-203.